– AUSTRALIA, Sydney – Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, today announced the appointment of Dr Alan W. Dunton, M.D., to its Board of Directors as an Independent Non-Executive Director and as a member of the Audit & Risk and Remuneration & Nomination Committees.
Dr. Dunton brings more than three decades of senior pharmaceutical experience leading clinical research development efforts, advancing drug candidates including a number of blockbuster antibiotics, through regulatory review and commercialization at fortune 500 companies including Johnson & Johnson and Roche.
“On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors,” said Non-Executive Chairman, Dr. John Prendergast.
He added: “Alan joins us at a critical time as we move into the second half of 2020, where we anticipate a number of human clinical trials evaluating our broad-spectrum novel antibiotic, RECCE 327. In addition, we will continue to investigate the efficacy of our synthetic compounds against SARS-CoV-2 among other key clinical development milestones. Alan’s biopharmaceutical industry experience with large pharma R&D organizations and public biotechnology companies, particularly commercialization of three antibiotics, two of which are now considered to be ‘blockbuster’ drugs, will be invaluable to Recce. We look forward to his guidance and counsel.”
About Dr Alan Dunton
Dr. Dunton has held leadership positions at various biotechnology and pharmaceutical companies including serving as president and CEO at Panacos Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., and COO at Emisphere Technologies, Inc. Dr. Dunton served in several positions at Johnson & Johnson including president and managing director at the Janssen Research Foundation, where he was responsible for leading over 2,000 professionals worldwide, and prior to this as vice president of global clinical research and development at the R.W. Johnson Pharmaceutical Research Institute.
Dr. Dunton said, “I am pleased to join Recce’s Board at such a pivotal time in the Company’s development, as its new classes of synthetic anti-infectives continue to show significant promise in tackling the global health problems of antibiotic-resistant superbugs and emerging viral pathogens. I look forward to supporting the Company in advancing its pipeline candidates through the clinic.”
Dr. Dunton earned his medical degree from New York University School of Medicine following his bachelor’s degree in biochemistry from the State University of New York at Buffalo. Dr. Dunton then completed his fellowship in clinical pharmacology at New York Hospital/Cornell University Medical Center and, in 1987, was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his work in medical ethics.
He currently serves on the boards of Oragenics, Inc., Palatin Technologies, Inc., Cormedix, Inc., and Regeneus, Ltd., an Australian clinical-stage company in the field of regenerative medicine.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd is pioneering the development and commercialization of new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce antibiotics are unique – their potency does not diminish even with repeated use, a common failure associated with existing antibiotics and their propensity to rapidly succumb to resistant superbugs.
For more information: https://www.recce.com.au
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.